Which has the lower trailing P/E, GSK or VRTX?

GSK has the lower trailing P/E: GSK trades at 16.72 and VRTX at 32.13. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, GSK or VRTX?

Over the past five years, VRTX grew revenue faster — GSK at a 1.38% CAGR versus VRTX at 13.57%.

Does GSK or VRTX pay a bigger dividend?

GSK pays a dividend (3.44% yield), while VRTX has no payments in the available dividend history.

Is GSK or VRTX more profitable?

VRTX runs the higher net margin — GSK at 14.52% versus VRTX at 34.89%.

How have GSK and VRTX total returns compared?

Over the past 10 years, GSK delivered 6.71% and VRTX delivered 18.87% annualized total return. Past performance doesn't predict future results.

GSK plc (GSK) vs Vertex Pharmaceuticals Incorporated (VRTX)

A side-by-side comparison of GSK plc and Vertex Pharmaceuticals Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 20, 2026. Differences are shown without an overall score or investment verdict.

GSK

GSK plc

$105.95B

$52.88HealthcareAt close: Aug 19, 2026, 4:00 PM ET

VRTX

Vertex Pharmaceuticals Incorporated

$140.12B

$552.06HealthcareAt close: Aug 19, 2026, 4:00 PM ET

Total return — GSK vs VRTX

growth of $100 · dividends reinvested · last 10y

GSK +94.1% (+6.9%/yr)VRTX +468.6% (+19.0%/yr)VRTX compounded faster over this window

GSK VRTX

GSK vs VRTX: by the numbers

•VRTX is the larger company ($140.12B vs $105.95B market cap).
•GSK trades at the lower trailing earnings multiple (16.72 vs 32.13 P/E), one valuation lens rather than an overall verdict.
•VRTX converts more revenue to profit (34.89% vs 14.52% net margin).
•VRTX grew revenue faster over the past five years (13.57% vs 1.38% CAGR).
•GSK pays a dividend (3.44% yield), while VRTX has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	GSK	VRTX
P/E ratio	16.72	32.13
Forward P/E	14.78	29.41
P/S ratio	2.42	11.18
P/B ratio	4.62	6.97
EV / EBITDA	8.56	26.91
FCF yield	8.69%	2.69%

Profitability

Metric	GSK	VRTX
Gross margin	72.71%	86.04%
Operating margin	20.72%	38.59%
Net margin	14.52%	34.89%
ROE	27.67%	21.76%
ROIC	13.95%	17.33%

Dividends

Metric	GSK	VRTX
Dividend yield	3.44%	N/A
Payout ratio	47.89%	N/A

Growth (annualized)

Metric	GSK	VRTX
Revenue CAGR (5Y)	1.38%	13.57%
EPS CAGR (5Y)	-0.71%	8.17%
FCF CAGR (5Y)	-2.45%	16.39%
Total return CAGR (5Y)	9.17%	23.14%

Frequently asked

Which has the lower trailing P/E, GSK or VRTX?: GSK has the lower trailing P/E: GSK trades at 16.72 and VRTX at 32.13. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, GSK or VRTX?: Over the past five years, VRTX grew revenue faster — GSK at a 1.38% CAGR versus VRTX at 13.57%.
Does GSK or VRTX pay a bigger dividend?: GSK pays a dividend (3.44% yield), while VRTX has no payments in the available dividend history.
Is GSK or VRTX more profitable?: VRTX runs the higher net margin — GSK at 14.52% versus VRTX at 34.89%.
How have GSK and VRTX total returns compared?: Over the past 10 years, GSK delivered 6.71% and VRTX delivered 18.87% annualized total return. Past performance doesn't predict future results.

Go deeper

Full GSK analysis Full VRTX analysis Interactive comparison tool

Dig into the metrics

GSK P/E ratio Vertex Pharmaceuticals P/E ratio GSK dividend yield GSK ROE Vertex Pharmaceuticals ROE GSK operating margin Vertex Pharmaceuticals operating margin GSK revenue growth Vertex Pharmaceuticals revenue growth GSK free cash flow Vertex Pharmaceuticals free cash flow

GSK & Vertex Pharmaceuticals appear in these rankings

Highest Dividend Yield Stocks Highest ROE Stocks Highest Operating Margin Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 20, 2026.